On August 3, the company reported positive results from its TELESTAR Phase 3 clinical trials. Results showed that the oral version of one of its main drugs candidate’s telotristat etiprate or LX1032 delivers a clinical benefit beyond what is possible with the current standard of care in the treatment of carcinoid syndrome patients. This is an addressable market that could see peak sales of $400 million to $550 million. The company also has other “shots on goal” and a market capitalization of just $1.3 billion. Does somebody follow this stock?
The company plans for the drug's regulatory approval with the U.S.Food and Drug Administration soon. Could be on the market sometime next year. I'm bullish here.